Nanoparticulate adjuvants and delivery systems for allergen immunotherapy
Palabras clave : 
Dendritic cells
Vaccine delivery
Biodegradable nanoparticles
Pla-peg particles
Coated chitosan nanoparticles
Fecha de publicación: 
Editorial : 
Hindawi Publishing Corporation
De Souza Reboucas J, Esparza I, Ferrer M, Luisa Sanz M, Manuel Irache J, Gamazo C. Nanoparticulate Adjuvants and Delivery Systems for Allergen Immunotherapy. J Biomed Biotechnol 2012:474605
In the last decades, significant progress in research and clinics has been made to offer possible innovative therapeutics for the management of allergic diseases. However, current allergen immunotherapy shows limitations concerning the long-term efficacy and safety due to local side effects and risk of anaphylaxis. Thus, effective and safe vaccines with reduced dose of allergen have been developed using adjuvants. Nevertheless, the use of adjuvants still has several disadvantages, which limits its use in human vaccines. In this context, several novel adjuvants for allergen immunotherapy are currently being investigated and developed. Currently, nanoparticles-based allergen-delivery systems have received much interest as potential adjuvants for allergen immunotherapy. It has been demonstrated that the incorporation of allergens into a delivery system plays an important role in the efficacy of allergy vaccines. Several nanoparticles-based delivery systems have been described, including biodegradable and nondegradable polymeric carriers. Therefore, this paper provides an overview of the current adjuvants used for allergen immunotherapy. Furthermore, nanoparticles-based allergen-delivery systems are focused as a novel and promising strategy for allergy vaccines.

Ficheros en este registro:
1,13 MB
Adobe PDF

Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.